Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach

Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach

Abstract Background FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GnP) have been recommended as the first-line chemotherapy for metastatic pancreatic cancer (mPC). However, the evidence is lacking comparing not only two regimens, but also sequential treatment (FFX–GnP vs. GnP–FFX). Methods D...

Full description

Bibliographic Details
Main Authors: Jung Won Chun, Sang Hyub Lee, Joo Seong Kim, Namyoung Park, Gunn Huh, In Rae Cho, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Cancer
Subjects:
Pancreatic neoplasms
Folfirinox
Albumin-bound paclitaxel
Survival
Online Access:https://doi.org/10.1186/s12885-021-08277-7

Internet

https://doi.org/10.1186/s12885-021-08277-7

Similar Items